We will now would like to start Daiichi Sankyo's Financial Results ... CEO, Manabe; Oncology Business Unit Head, Ken Keller; and Oncology business heads for the US and Europe will be on stage ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan ... another paradigm shift in how certain breast cancers can be treated,” said Ken Keller, global head, oncology ...

Datroway is the latest addition to our portfolio of innovative cancer treatments and marks the fourth medicine from our oncology pipeline to receive approval in the US,” said Ken Keller, global head, ...

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this month the company has secured an approval for AstraZeneca-partnered Dato-DXd, ...

WILMINGTON, Del., January 17, 2025--(BUSINESS WIRE)--DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu ... options in the late-line setting," commented Ken Keller, Daiichi Sankyo's head of oncology.

One of the best single talks of the show for me was Daiichi Sankyo CEO Ken Keller, who told the story of how his company restructured around oncology when it became apparent how much opportunity ...

His legacy of helping others is carried by all of us at Daiichi Sankyo US. Thank you, Agatsuma-san for sharing your gift with us; it’s an honor of a lifetime to have worked with you. We will ...

Tokyo: D aichi Sankyo has announced that DATROWAY (datopotamab deruxtecan ... TROP2 directed antibody drug conjugate earlier in the metastatic setting,” said Ken Keller, Global Head of Oncology ...

The approval “represents another paradigm shift in how certain breast cancers can be treated,” said Ken Keller, Daiichi Sankyo’s president and CEO, in a statement. Enhertu, which delivers a toxin to ...

DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE ... drug conjugate earlier in the metastatic setting,” said Ken Keller, Global ...